<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244242</url>
  </required_header>
  <id_info>
    <org_study_id>527.16</org_study_id>
    <nct_id>NCT02244242</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Symptomatic Relief Effects of FLOMAX速 in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX速 Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate the symptomatic relief afforded by tamsulosin hydrochloride capsules in&#xD;
      patients with signs and symptoms of benign prostatic hyperplasia (BPH). Additionally to&#xD;
      provide primary care physicians experience with the use of tamsulosin hydrochloride capsules&#xD;
      0.4 mg daily for the treatment of BPH&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <primary_completion_date type="Actual">August 1999</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in American Urological Association (AUA) Symptom Score Index by means of a patient self-assessment questionnaire</measure>
    <time_frame>up to 45 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of AUA Bother Score Index by means of a patient self-assessment questionnaire</measure>
    <time_frame>up to 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BPH Impact Index by means of a patient self-assessment questionnaire</measure>
    <time_frame>up to 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of investigator on 5-point scale</measure>
    <time_frame>at 4, 8 and 45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 59 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">493</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tamsulosin hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified release capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin hydrochloride</intervention_name>
    <arm_group_label>Tamsulosin hydrochloride</arm_group_label>
    <other_name>Flomax速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male patients (45 years of age or older) diagnosed with BPH who scores at least 13&#xD;
             points on the AUA Symptom Score Index at baseline&#xD;
&#xD;
          -  Patients who have a baseline Prostate specific antigen (PSA) of &gt;= 4.0 ng/ml&#xD;
&#xD;
          -  Patients who provide written informed consent prior to participation in the study in&#xD;
             accordance with regulatory requirements&#xD;
&#xD;
          -  Patients who have been judged by the investigator to be reliable and who have agreed&#xD;
             to cooperate with all tests and examinations stipulated in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously been diagnosed with prostate cancer&#xD;
&#xD;
          -  Patients who have an abnormal Digital rectal examination (DRE) of the prostate gland&#xD;
             at baseline other than enlargement (i.e., patients with suspicious areas or nodularity&#xD;
             of the gland which may indicate possible prostatic carcinoma are to be excluded)&#xD;
&#xD;
          -  Patients who have had previous invasive or non-invasive surgical treatment of the&#xD;
             prostate gland&#xD;
&#xD;
          -  Patients who have had an episode of acute urinary retention within four weeks of the&#xD;
             screening visit&#xD;
&#xD;
          -  Patients who have a history or evidence of urethral stricture&#xD;
&#xD;
          -  Patients who have had pelvic radiotherapy&#xD;
&#xD;
          -  Patients who have a history of chronic prostatitis&#xD;
&#xD;
          -  Patients who have a history of neurogenic bladder&#xD;
&#xD;
          -  Patients who have had a urinary tract infection (i.e. positive urine culture yielding&#xD;
             pathogenic bacteria &gt;= 10**5 colony forming units per ml or a laboratory report of a&#xD;
             urinary tract infection) or symptoms/signs indicative of a urinary tract infection&#xD;
             such as: increased white blood cells (WBCs) in the urine (15-30 WBC/high powered field&#xD;
             [hpf], dysuria, costovertebral tenderness and urinary frequency accompanied by fever&#xD;
             within four weeks of baseline&#xD;
&#xD;
          -  Patients who have evidence of significant renal dysfunction based upon a serum&#xD;
             creatinine greater than two times the upper limit of normal levels established by the&#xD;
             central laboratory used in this study&#xD;
&#xD;
          -  Patients who have baseline clinical laboratory test results that indicate the&#xD;
             following values:&#xD;
&#xD;
               -  Hemoglobin: &lt; 12.0 g/dl&#xD;
&#xD;
               -  Leukocytes: &lt; 3000 mm続&#xD;
&#xD;
               -  Liver enzymes: Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic&#xD;
                  Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) and alkaline&#xD;
                  phosphatase): More than two times the upper limit of normal levels established by&#xD;
                  the central laboratory used in the study&#xD;
&#xD;
          -  Patients who have postural symptoms (e.g. lightheadedness, dizziness and fainting&#xD;
             occurring with or without a change in Blood Pressure (BP) and/or Heart Rate (HR)&#xD;
             within four weeks of baseline&#xD;
&#xD;
          -  Patients who have participated in another drug study within four weeks of baseline&#xD;
&#xD;
          -  Patients who have clinically relevant conditions which might interfere with the&#xD;
             patient's ability to participate in the study including (but not limited to) the&#xD;
             following:&#xD;
&#xD;
               -  neurologic, gastrointestinal, cardiovascular (including uncontrolled hypertension&#xD;
                  defined as a sitting diastolic BP &gt;= 95 mmHg with or without treatment), hepatic,&#xD;
                  renal, psychiatric, hematologic or respiratory disease or clinically relevant&#xD;
                  laboratory abnormalities based upon the investigator's judgment&#xD;
&#xD;
          -  Patients who have had cancer or a diagnosis of cancer within five years of baseline&#xD;
&#xD;
          -  Patients who have received cimetidine, warfarin or herbal medication specifically for&#xD;
             treatment of any urological problems within four weeks prior or baseline&#xD;
&#xD;
          -  Patients who have known allergy to study medication&#xD;
&#xD;
          -  Patients who are currently receiving finasteride or who have been treated with&#xD;
             finasteride within three months prior to baseline&#xD;
&#xD;
          -  Patients who have documented myocardial infarction (by ECG) within the past 6 months&#xD;
             or evidence of a myocardial infarction on an ECG where the date could not be&#xD;
             determined&#xD;
&#xD;
          -  Patients who are classified as New York Heart Association (NYHA) Class III or IV&#xD;
             congestive heart failure&#xD;
&#xD;
          -  Patients who have prosthetic heart valves, cardiac devices or history of endocarditis&#xD;
&#xD;
          -  Patient who have clinically significant cardiac arrhythmias as diagnosed by ECG&#xD;
             whether or not accompanied by symptoms (e.g., dizziness, presyncope, syncope,&#xD;
             unsteadiness)&#xD;
&#xD;
          -  Patients who have received the following drugs within two weeks prior to baseline and&#xD;
             who are unable to discontinue these drugs for the remainder of the study:&#xD;
&#xD;
               1. Alpha-adrenergic blocking agents&#xD;
&#xD;
               2. Alpha-adrenergic agonists&#xD;
&#xD;
               3. Drugs with anticholinergic activity including antihistamines&#xD;
&#xD;
               4. Antispasmodics&#xD;
&#xD;
               5. Parasympathomimetics and cholinomimetics&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

